ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting

The biomarker is the first to predict long-term ADT usage in men with high-risk localized prostate cancer

SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announces new data validating a multimodal AI-derived predictive biomarker, which has been selected as an oral presentation at the 2023 ASCO annual meeting. The biomarker demonstrated the ability to predict the benefit of long-term androgen deprivation therapy (ADT) in men with localized high-risk prostate cancer.

In patients with high-risk localized prostate cancer, ADT is considered a cornerstone of treatment, along with radiotherapy. When making treatment decisions, clinicians and patients must consider the duration of therapy, which is known to have a wide range of negative side effects. To help guide a treatment plan that will maximize benefits and minimize risks, predictive biomarkers are needed. The authors of the research, including Dr. Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University, sought to develop an AI-based predictive biomarker to address this unmet need.

“This is the first-ever AI-derived biomarker that can predict clinical benefit from longer-duration therapy,” said Dr. Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University and lead author of this research. “We are eager for the further development of this biomarker as it could lead to a tool that has the potential to change how clinicians make treatment decisions. Furthermore, it could help save patients from the physical, emotional, and financial burden of a long-term treatment that would not have therapeutic benefit.”

Clinical data and histopathology image data from pretreatment prostate biopsy slides were used to train the model to predict the benefit of long-term vs short-term ADT treatment on distant metastasis. Developed using patient data from six randomized, phase 3 NRG/RTOG trials of men receiving RT +/- ADT, the AI-derived predictive biomarker identified 34% of men that could derive similar benefit with short-term ADT, avoiding the side effects of prolonged ADT. Additionally, the model identified 43% of intermediate-risk men who would benefit from long-term ADT.

For more information on ArteraAI, visit Artera.ai.

About ArteraAI

ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test.

ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis and has been validated in many phase 3 randomized trials.

ArteraAI Prostate Test is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer. The test is clinically available through our CLIA-certified laboratory in Jacksonville, Florida and can be ordered online at Artera.ai.